See more : PATRIZIA SE (PTZIF) Income Statement Analysis – Financial Results
Complete financial analysis of Amgen Inc. (AMGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amgen Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- GAN Limited (GAN) Income Statement Analysis – Financial Results
- BioLASCO Taiwan Co., Ltd. (6662.TWO) Income Statement Analysis – Financial Results
- Pacific Metals Co., Ltd. (5541.T) Income Statement Analysis – Financial Results
- Engineers India Limited (ENGINERSIN.NS) Income Statement Analysis – Financial Results
- Petrotx – Limited Partnership (PTX.TA) Income Statement Analysis – Financial Results
Amgen Inc. (AMGN)
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.19B | 26.32B | 25.98B | 25.42B | 23.36B | 23.75B | 22.85B | 22.99B | 21.66B | 20.06B | 18.68B | 17.27B | 15.58B | 15.05B | 14.64B | 15.00B | 14.77B | 14.27B | 12.43B | 10.55B | 8.36B | 5.52B | 4.02B | 3.45B | 3.20B | 2.64B | 2.35B | 2.20B | 1.90B | 1.62B | 1.35B | 1.08B | 679.80M | 190.40M | 70.20M | 44.30M | 29.80M | 21.10M |
| Cost of Revenue | 8.42B | 6.41B | 6.45B | 6.16B | 4.36B | 4.10B | 4.07B | 4.16B | 4.23B | 4.42B | 3.35B | 2.92B | 2.43B | 2.22B | 2.09B | 2.30B | 2.55B | 2.10B | 2.08B | 1.73B | 1.34B | 735.70M | 443.00M | 196.60M | 225.30M | 201.40M | 183.70M | 182.90M | 188.70M | 163.60M | 169.30M | 151.20M | 91.20M | 14.70M | 44.00M | 35.50M | 21.80M | -2.50M |
| Gross Profit | 19.78B | 19.92B | 19.53B | 19.27B | 19.01B | 19.65B | 18.78B | 18.83B | 17.44B | 15.64B | 15.33B | 14.35B | 13.16B | 12.83B | 12.55B | 12.71B | 12.22B | 12.17B | 10.35B | 8.82B | 7.02B | 4.79B | 3.57B | 3.25B | 2.98B | 2.44B | 2.16B | 2.02B | 1.72B | 1.46B | 1.19B | 929.10M | 588.60M | 175.70M | 26.20M | 8.80M | 8.00M | 23.60M |
| Gross Profit Ratio | 70.15% | 75.66% | 75.16% | 75.77% | 81.35% | 82.73% | 82.19% | 81.90% | 80.49% | 77.96% | 82.08% | 83.10% | 84.42% | 85.25% | 85.72% | 84.70% | 82.75% | 85.32% | 83.25% | 83.59% | 83.96% | 86.68% | 88.97% | 94.30% | 92.97% | 92.38% | 92.17% | 91.68% | 90.09% | 89.90% | 87.50% | 86.00% | 86.58% | 92.28% | 37.32% | 19.86% | 26.85% | 111.85% |
| Research & Development | 4.78B | 4.43B | 4.82B | 4.21B | 4.12B | 3.74B | 3.56B | 3.84B | 4.07B | 4.30B | 4.08B | 3.38B | 3.17B | 2.89B | 2.86B | 3.03B | 3.27B | 3.37B | 2.31B | 2.03B | 1.66B | 1.12B | 865.00M | 845.00M | 822.80M | 663.30M | 630.80M | 528.30M | 451.70M | 323.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.52B | 4.57B | 4.53B | 4.77B | 4.36B | 5.33B | 4.87B | 5.06B | 4.85B | 4.70B | 5.18B | 4.80B | 4.49B | 3.98B | 3.82B | 3.79B | 3.36B | 3.37B | 2.79B | 2.56B | 1.95B | 1.46B | 970.70M | 826.90M | 654.30M | 515.40M | 483.80M | 470.60M | 418.40M | 359.80M | 583.70M | 397.40M | 0.00 | 134.60M | 23.00M | 10.30M | 6.80M | 22.00M |
| Selling & Marketing | 647.00M | 841.00M | 843.00M | 962.00M | 789.00M | 674.00M | 620.00M | 489.00M | 346.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.18B | 5.41B | 5.37B | 5.73B | 5.15B | 5.33B | 4.87B | 5.06B | 4.85B | 4.70B | 5.18B | 4.80B | 4.49B | 3.98B | 3.82B | 3.79B | 3.36B | 3.37B | 2.79B | 2.56B | 1.95B | 1.46B | 970.70M | 826.90M | 654.30M | 515.40M | 483.80M | 470.60M | 418.40M | 359.80M | 583.70M | 397.40M | 443.70M | 134.60M | 23.00M | 10.30M | 6.80M | 22.00M |
| Other Expenses | 915.00M | 503.00M | 194.00M | 189.00M | 66.00M | 314.00M | 375.00M | 133.00M | 49.00M | 454.00M | 196.00M | 589.00M | 294.00M | 411.00M | 361.00M | 674.00M | 817.00M | 370.00M | 396.00M | 333.00M | 316.10M | -7.09B | 205.80M | 211.80M | 176.80M | 143.80M | 117.10M | 100.30M | 84.20M | 74.50M | 50.70M | 33.60M | 21.50M | 12.00M | 8.00M | 4.10M | 2.60M | 2.50M |
| Operating Expenses | 11.88B | 10.35B | 10.38B | 10.13B | 9.33B | 9.38B | 8.81B | 9.04B | 8.97B | 9.45B | 9.46B | 8.77B | 8.84B | 7.29B | 7.05B | 7.49B | 7.44B | 7.10B | 5.50B | 4.92B | 3.92B | -4.51B | 2.04B | 1.88B | 1.65B | 1.32B | 1.23B | 1.10B | 954.30M | 757.90M | 634.40M | 431.00M | 465.20M | 146.60M | 31.00M | 14.40M | 9.40M | 24.50M |
| Cost & Expenses | 20.29B | 16.76B | 16.84B | 16.29B | 13.69B | 13.48B | 12.88B | 13.20B | 13.19B | 13.87B | 12.81B | 11.69B | 11.27B | 9.51B | 9.14B | 9.79B | 9.99B | 9.20B | 7.58B | 6.65B | 5.26B | -3.78B | 2.48B | 2.08B | 1.88B | 1.52B | 1.42B | 1.28B | 1.14B | 921.50M | 803.70M | 582.20M | 556.40M | 161.30M | 75.00M | 49.90M | 31.20M | 22.00M |
| Interest Income | 0.00 | 1.41B | 1.20B | 256.00M | 753.00M | 674.00M | 928.00M | 629.00M | 603.00M | 465.00M | 420.00M | 485.00M | 448.00M | 376.00M | 276.00M | 145.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.88B | 1.41B | 1.20B | 1.26B | 1.29B | 1.39B | 1.30B | 1.26B | 1.10B | 1.07B | 1.02B | 1.05B | 610.00M | 604.00M | 578.00M | 344.00M | 2.14B | 2.28B | 29.00M | 1.06B | 0.00 | 12.83B | 0.00 | 0.00 | 0.00 | 0.00 | 134.10M | 0.00 | 0.00 | 208.40M | 0.00 | 0.00 | 0.00 | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.07B | 3.26B | 3.40B | 3.60B | 2.21B | 1.95B | 1.90B | 2.11B | 2.11B | 2.09B | 1.29B | 294.00M | 294.00M | 294.00M | 294.00M | 1.07B | 1.20B | 963.00M | 841.00M | 734.00M | 686.50M | 447.30M | 265.90M | 211.80M | 176.80M | 143.80M | 117.10M | 100.30M | 84.20M | 74.50M | 50.70M | 33.60M | 21.50M | 12.00M | 8.00M | 4.10M | 2.60M | 2.50M |
| EBITDA | 14.70B | 12.09B | 12.54B | 12.93B | 12.63B | 12.88B | 12.80B | 11.94B | 11.13B | 8.75B | 7.39B | 6.36B | 5.05B | 6.67B | 6.58B | 6.64B | 5.98B | 7.27B | 5.69B | 4.17B | 3.78B | 2.65B | 1.80B | 1.58B | 1.50B | 1.26B | 1.05B | 1.02B | 845.00M | 773.00M | 601.90M | 531.70M | 144.90M | 68.80M | 3.20M | -1.50M | 1.20M | 1.60M |
| EBITDA Ratio | 52.15% | 33.25% | 36.19% | 36.95% | 44.63% | 46.06% | 47.71% | 45.34% | 41.88% | 33.18% | 33.66% | 36.81% | 32.43% | 41.29% | 41.50% | 44.44% | 49.41% | 50.92% | 46.16% | 49.19% | 44.97% | 228.08% | 43.58% | 40.71% | 41.62% | 43.38% | 47.43% | 43.85% | 41.82% | 53.78% | 40.93% | 43.19% | 16.03% | 19.70% | 7.55% | -21.44% | -6.04% | 14.69% |
| Operating Income | 7.90B | 5.34B | 6.01B | 5.79B | 9.67B | 10.26B | 9.97B | 9.79B | 8.47B | 6.19B | 5.87B | 5.58B | 4.31B | 5.55B | 5.51B | 5.21B | 3.98B | 3.84B | 4.85B | 3.35B | 3.09B | 6.31B | 1.53B | 1.37B | 1.33B | 1.12B | 930.30M | 916.00M | 760.80M | 698.50M | 551.20M | 498.10M | 123.40M | 29.10M | -4.80M | -5.60M | -1.40M | -900.00K |
| Operating Income Ratio | 28.01% | 20.27% | 23.11% | 22.79% | 41.41% | 43.22% | 43.65% | 42.60% | 39.10% | 30.86% | 31.41% | 32.30% | 27.67% | 36.84% | 37.60% | 34.75% | 26.94% | 26.91% | 39.00% | 31.73% | 36.99% | 114.20% | 38.13% | 39.67% | 41.35% | 42.33% | 39.66% | 41.67% | 39.96% | 43.12% | 40.68% | 46.11% | 18.15% | 15.28% | -6.84% | -12.64% | -4.70% | -4.27% |
| Total Other Income/Expenses | -42.00M | 2.01B | 696.00M | -1.01B | -536.00M | -718.00M | -376.00M | -631.00M | -492.00M | -606.00M | -602.00M | -960.00M | -162.00M | -228.00M | -302.00M | -199.00M | -1.64B | -1.04B | 20.00M | -840.00M | 81.80M | -2.89B | 155.10M | 306.20M | 241.20M | 106.00M | -68.90M | 46.30M | 33.60M | -110.20M | 41.20M | 65.00M | 34.60M | 43.30M | -2.60M | 7.60M | 3.00M | 1.50M |
| Income Before Tax | 7.86B | 7.35B | 6.70B | 8.13B | 9.14B | 9.55B | 9.60B | 9.16B | 7.98B | 5.59B | 5.27B | 5.01B | 4.15B | 5.32B | 5.20B | 5.25B | 3.96B | 4.02B | 4.87B | 3.40B | 3.17B | -684.50M | 1.69B | 1.67B | 1.57B | 1.22B | 861.40M | 962.30M | 794.40M | 588.30M | 592.40M | 563.10M | 158.00M | 29.40M | -7.40M | 2.00M | 1.60M | 600.00K |
| Income Before Tax Ratio | 27.86% | 27.91% | 25.79% | 31.99% | 39.11% | 40.19% | 42.00% | 39.85% | 36.83% | 27.84% | 28.19% | 29.01% | 26.63% | 35.32% | 35.54% | 34.99% | 26.82% | 28.17% | 39.16% | 32.18% | 37.97% | -12.39% | 41.99% | 48.55% | 48.88% | 46.34% | 36.72% | 43.78% | 41.73% | 36.31% | 43.72% | 52.12% | 23.24% | 15.44% | -10.54% | 4.51% | 5.37% | 2.84% |
| Income Tax Expense | 1.14B | 794.00M | 808.00M | 869.00M | 1.30B | 1.15B | 7.62B | 1.44B | 1.04B | 427.00M | 184.00M | 664.00M | 467.00M | 690.00M | 599.00M | 1.05B | 795.00M | 1.07B | 1.19B | 1.03B | 913.60M | 707.40M | 566.60M | 535.80M | 469.80M | 361.20M | 217.10M | 282.50M | 256.70M | 268.60M | 217.80M | 205.50M | 60.10M | 10.30M | 800.00K | 300.00K | 800.00K | 100.00K |
| Net Income | 6.72B | 6.55B | 5.89B | 7.26B | 7.84B | 8.39B | 1.98B | 7.72B | 6.94B | 5.16B | 5.08B | 4.35B | 3.68B | 4.63B | 4.61B | 4.20B | 3.17B | 2.95B | 3.67B | 2.36B | 2.26B | -1.39B | 1.12B | 1.14B | 1.10B | 863.20M | 644.30M | 679.80M | 537.70M | 319.70M | 383.30M | 357.60M | 97.90M | 19.10M | -8.20M | 1.70M | 800.00K | 500.00K |
| Net Income Ratio | 23.83% | 24.89% | 22.68% | 28.57% | 33.57% | 35.35% | 8.66% | 33.59% | 32.03% | 25.71% | 27.21% | 25.17% | 23.64% | 30.74% | 31.45% | 27.97% | 21.43% | 20.68% | 29.56% | 22.40% | 27.04% | -25.20% | 27.88% | 33.02% | 34.22% | 32.67% | 27.47% | 30.93% | 28.24% | 19.73% | 28.29% | 33.10% | 14.40% | 10.03% | -11.68% | 3.84% | 2.68% | 2.37% |
| EPS | 12.56 | 12.18 | 10.34 | 12.40 | 12.96 | 12.70 | 2.71 | 10.32 | 9.15 | 6.80 | 6.75 | 5.61 | 4.07 | 4.82 | 4.53 | 3.79 | 2.83 | 2.51 | 2.97 | 1.86 | 1.75 | -1.21 | 1.07 | 1.11 | 1.07 | 0.85 | 0.61 | 0.61 | 0.48 | 0.29 | 0.35 | 0.31 | 0.09 | 0.03 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 12.49 | 12.11 | 10.28 | 12.31 | 12.88 | 12.62 | 2.69 | 10.24 | 9.06 | 6.70 | 6.64 | 5.52 | 4.04 | 4.79 | 4.51 | 3.77 | 2.82 | 2.48 | 2.93 | 1.81 | 1.69 | -1.21 | 1.03 | 1.05 | 1.02 | 0.82 | 0.59 | 0.61 | 0.47 | 0.28 | 0.35 | 0.31 | 0.09 | 0.03 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 535.00M | 538.00M | 570.00M | 586.00M | 605.00M | 661.00M | 731.00M | 748.00M | 758.00M | 759.00M | 753.00M | 775.00M | 905.00M | 960.00M | 1.02B | 1.07B | 1.12B | 1.18B | 1.24B | 1.27B | 1.29B | 1.15B | 1.05B | 1.03B | 1.02B | 1.02B | 1.06B | 1.12B | 1.12B | 1.12B | 1.10B | 1.15B | 1.09B | 636.67M | 820.00M | 940.86M | 940.86M | 940.86M |
| Weighted Avg Shares Out (Dil) | 538.00M | 541.00M | 573.00M | 590.00M | 609.00M | 665.00M | 735.00M | 754.00M | 766.00M | 770.00M | 765.00M | 787.00M | 912.00M | 965.00M | 1.02B | 1.08B | 1.12B | 1.19B | 1.26B | 1.32B | 1.35B | 1.15B | 1.08B | 1.08B | 1.08B | 1.06B | 1.10B | 1.12B | 1.14B | 1.13B | 1.10B | 1.15B | 1.09B | 636.67M | 820.00M | 940.86M | 940.86M | 940.86M |
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS
Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Why Amgen (AMGN) Dipped More Than Broader Market Today
Is Amgen Stock a Buy?
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Source: https://incomestatements.info
Category: Stock Reports